Skip to main content
. 2022 Jul 19;37(1):2017–2035. doi: 10.1080/14756366.2022.2101645

Table 3.

Structure and activities of C series compounds. Inline graphic

Componds R3 PCSK9a HepG2a
C1 graphic file with name IENZ_A_2101645_ILG0041_B.jpg 21.6 ± 1.67 6.21 ± 0.22
C2 graphic file with name IENZ_A_2101645_ILG0042_B.jpg 17.8 ± 1.24 13.52 ± 1.13
C3 graphic file with name IENZ_A_2101645_ILG0043_B.jpg 25.3 ± 2.11 6.62 ± 0.45
C4 graphic file with name IENZ_A_2101645_ILG0044_B.jpg 7.55 ± 0.71 6.77 ± 0.62
C5 graphic file with name IENZ_A_2101645_ILG0045_B.jpg 5.92 ± 0.32 5.63 ± 0.37
C6 graphic file with name IENZ_A_2101645_ILG0046_B.jpg 3.39 ± 1.67 6.15 ± 0.26
C7 graphic file with name IENZ_A_2101645_ILG0047_B.jpg 33.4 ± 1.52 12.85 ± 1.07
C8 graphic file with name IENZ_A_2101645_ILG0048_B.jpg 25.7 ± 1.20 14.54 ± 1.22
C9 graphic file with name IENZ_A_2101645_ILG0049_B.jpg 3.75 ± 0.33 6.22 ± 0.24
C10 graphic file with name IENZ_A_2101645_ILG0050_B.jpg 5.48 ± 0.20 6.76 ± 0.18
PCSK9 neutralising antibody – IC50 = 7.8 nM ND
SAHA – ND 89.2 ± 1.76
a

Illustrated as percentage inhibitory rate at concentration of 10 µM, and each value is the mean of three experiments. ND: Not determined.